Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026.

Guideline ID: 923 Published: 2026 Jan 1

American Diabetes Association (ADA)

American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026 Jan 1;49(Supplement_1):S183-S215. [318 references] PubMed

View Original Guideline

Overview

Guideline Objective

- To provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care
- To offer guidance on pharmacologic approaches to glycemic treatment in type 1 and type 2 diabetes

Patient Population

Adult patients with type 1 and type 2 diabetes

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Treatment of type 1 diabetes, including selection of agents, administration techniques, education, and reevaluation of insulin treatment plan and insulin-taking behavior
- Treatment of type 2 diabetes, including choice of glucose-lowering therapy, combination therapy, and consideration of comorbidities
- Guidance on special populations/circumstances, including individuals of childbearing potential, individuals receiving cancer treatment, and individuals who are at risk for developing diabetic ketoacidosis

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Introduction and Methodology: *Standards of Care in Diabetes—2026*; 2026 Jan 1.
- Summary of Revisions: *Standards of Care in Diabetes—2026*; 2026 Jan 1.
- Disclosures: *Standards of Care in Diabetes—2026*; 2026 Jan 1.

Implementation Tools

- Slide Set: *Standards of Care in Diabetes—2026*; 2026.
- Standards of Care App for iOS or Android.
- Continuing Medical Education.
- The Original Guideline includes the following:
    - Figure 9.2. Insulin Initiation and Adjustment for People with Type 1 Diabetes using Multiple Daily Dosing (p. S188)
    - Figure 9.3. Simplified Overview of Indications for β-cell Replacement Therapy in People with Type 1 Diabetes (p. S190)
    - Figure 9.4. Use of Glucose-lowering Medications in the Management of Type 2 Diabetes (p. S191)
    - Figure 9.5. Intensifying to Injectable Therapies in Type 2 Diabetes (p. S198)

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2026 ECRI